These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 25727756

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
    Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D.
    World J Gastroenterol; 2015 Feb 14; 21(6):1945-55. PubMed ID: 25684964
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
    Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB.
    J Med Econ; 2017 Sep 14; 20(9):945-951. PubMed ID: 28562131
    [Abstract] [Full Text] [Related]

  • 6. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.
    Lau SC, Abdel-Rahman O, Cheung WY.
    Med Oncol; 2018 Aug 04; 35(9):123. PubMed ID: 30078166
    [Abstract] [Full Text] [Related]

  • 7. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF.
    Ann Oncol; 2000 Sep 04; 11(9):1127-30. PubMed ID: 11061606
    [Abstract] [Full Text] [Related]

  • 8. The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy.
    Dogliotti L, Tampellini M, Stivanello M, Gorzegno G, Fabiani L.
    Ann Oncol; 2001 Sep 04; 12 Suppl 2():S105-9. PubMed ID: 11762334
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski PB, Van Cutsem E, Öberg K, Pavel ME.
    Endocr Relat Cancer; 2015 Dec 04; 22(6):933-40. PubMed ID: 26373569
    [Abstract] [Full Text] [Related]

  • 10. Dose escalation of octreotide LAR is safe and effective in patients with advanced gastrointestinal neuroendocrine tumours for control of symptoms and tumor progression.
    Verslype C.
    Acta Gastroenterol Belg; 2011 Mar 04; 74(1):93-4. PubMed ID: 21563661
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K.
    Drug Des Devel Ther; 2015 Mar 04; 9():5075-86. PubMed ID: 26366058
    [Abstract] [Full Text] [Related]

  • 14. Rheumatoid arthritis associated with the use of Sandostatin® LAR® depot in a patient with pancreatic neuroendocrine tumor. An association or a coincidence? The first case report.
    Saif MW.
    JOP; 2011 Jul 08; 12(4):425-8. PubMed ID: 21737909
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors.
    Woltering EA, Mamikunian PM, Zietz S, Krutzik SR, Go VL, Vinik AI, Vinik E, O'Dorisio TM, Mamikunian G.
    Pancreas; 2005 Nov 08; 31(4):392-400. PubMed ID: 16258376
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
    Anthony LB, Pavel ME, Hainsworth JD, Kvols LK, Segal S, Hörsch D, Van Cutsem E, Öberg K, Yao JC.
    Neuroendocrinology; 2015 Nov 08; 102(1-2):18-25. PubMed ID: 25824001
    [Abstract] [Full Text] [Related]

  • 19. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.
    Shen C, Shih YC, Xu Y, Yao JC.
    Cancer Epidemiol Biomarkers Prev; 2015 Nov 08; 24(11):1656-65. PubMed ID: 26315553
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.